ArticleFrontiers in endocrinology2022

HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study.

Yingbo Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.